$DARE News

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dare Biosciences Receives Second $1M Tranche Of NIH Funding

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

Daré Bioscience Initiates Phase 2 Clinical Study Of DARE-HPV Treatment

Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...

Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript

Daré Bioscience (NASDAQ:DARE) Q1 2026 Results Show Mixed Bag with Revenue Miss but EPS Beat and Upcoming Product Launches

Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

Dare Bioscience Q1 2026 Earnings Call: Complete Transcript

Dare Bioscience Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $152.455K Miss $984.667K Estimate

Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Dare Bioscience Announces Interim Safety And Efficacy Results From Phase 3 Clinical Trial Of Ovaprene

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

Let's uncover which stocks are experiencing notable gaps during today's session.

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript

Daré Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation

Dare Bioscience Q4 EPS $(0.02) Beats $(0.43) Estimate, Sales $1.024M Beat $375.750K Estimate

On National Viagra Day, Women Finally Claim Their Turn: